IS8224A - Amínsölt (-)-2-{[2-(4-hýdroxýfenýl)etýl]-þíó}-3-[4-(2-{4-[(metýlsúlfónýl)oxý]fenoxý}etýl)fenýl]própansýru og notkun þeirra í læknisfræði - Google Patents

Amínsölt (-)-2-{[2-(4-hýdroxýfenýl)etýl]-þíó}-3-[4-(2-{4-[(metýlsúlfónýl)oxý]fenoxý}etýl)fenýl]própansýru og notkun þeirra í læknisfræði

Info

Publication number
IS8224A
IS8224A IS8224A IS8224A IS8224A IS 8224 A IS8224 A IS 8224A IS 8224 A IS8224 A IS 8224A IS 8224 A IS8224 A IS 8224A IS 8224 A IS8224 A IS 8224A
Authority
IS
Iceland
Prior art keywords
ethyl
methylsulfonyl
thio
hydroxyphenyl
phenoxy
Prior art date
Application number
IS8224A
Other languages
English (en)
Inventor
Ahlqvist Matti
Ulf Johan Dahlstrom Mikael
Ohlsson Bengt
Anthony Storey Richard
Philip Taylor Nigel
Woods Rebecca
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS8224A publication Critical patent/IS8224A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/56—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
IS8224A 2003-06-18 2006-01-10 Amínsölt (-)-2-{[2-(4-hýdroxýfenýl)etýl]-þíó}-3-[4-(2-{4-[(metýlsúlfónýl)oxý]fenoxý}etýl)fenýl]própansýru og notkun þeirra í læknisfræði IS8224A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0314130.6A GB0314130D0 (en) 2003-06-18 2003-06-18 Therapeutic agents
PCT/GB2004/002576 WO2004113283A1 (en) 2003-06-18 2004-06-16 Amine salts of (-)-2-{`2-(4-hydroxyphenyl) ethyl!-thio}-3-`4-(2-{4-`(methylsulfonyl)oxy! phenoxy}ethyl)phenyl! propanoic acid and there use in medicine

Publications (1)

Publication Number Publication Date
IS8224A true IS8224A (is) 2006-01-10

Family

ID=27636789

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8224A IS8224A (is) 2003-06-18 2006-01-10 Amínsölt (-)-2-{[2-(4-hýdroxýfenýl)etýl]-þíó}-3-[4-(2-{4-[(metýlsúlfónýl)oxý]fenoxý}etýl)fenýl]própansýru og notkun þeirra í læknisfræði

Country Status (20)

Country Link
US (1) US20070099928A1 (is)
EP (1) EP1638930A1 (is)
JP (1) JP3927594B2 (is)
KR (1) KR20060023165A (is)
CN (1) CN1835919A (is)
AR (1) AR044826A1 (is)
AU (1) AU2004249483A1 (is)
BR (1) BRPI0411580A (is)
CA (1) CA2529544A1 (is)
CO (1) CO5630026A2 (is)
GB (1) GB0314130D0 (is)
IL (1) IL172633A0 (is)
IS (1) IS8224A (is)
MX (1) MXPA05013718A (is)
NO (1) NO20056006L (is)
RU (1) RU2005141061A (is)
TW (1) TW200503671A (is)
UY (1) UY28372A1 (is)
WO (1) WO2004113283A1 (is)
ZA (1) ZA200510263B (is)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0104333D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
EP1517883B8 (en) 2002-06-20 2008-05-21 AstraZeneca AB Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
GB0314131D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314075D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0427524D0 (en) 2004-12-16 2005-01-19 Astrazeneca Ab Chemical process
GB0427701D0 (en) * 2004-12-17 2005-01-19 Astrazeneca Ab Therapeutic agents
JP5662682B2 (ja) * 2007-01-18 2015-02-04 エヴォルヴァ エスアー Ｐｐａｒモジュレータとして有用な置換１，３−ジオキサン

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9801992D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
MA26634A1 (fr) * 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
SE0104333D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents

Also Published As

Publication number Publication date
AR044826A1 (es) 2005-10-05
KR20060023165A (ko) 2006-03-13
MXPA05013718A (es) 2006-06-27
AU2004249483A1 (en) 2004-12-29
TW200503671A (en) 2005-02-01
ZA200510263B (en) 2007-02-28
JP3927594B2 (ja) 2007-06-13
JP2006527749A (ja) 2006-12-07
CN1835919A (zh) 2006-09-20
CO5630026A2 (es) 2006-04-28
GB0314130D0 (en) 2003-07-23
US20070099928A1 (en) 2007-05-03
IL172633A0 (en) 2006-04-10
NO20056006L (no) 2006-02-24
WO2004113283A1 (en) 2004-12-29
BRPI0411580A (pt) 2006-08-08
EP1638930A1 (en) 2006-03-29
RU2005141061A (ru) 2006-08-27
UY28372A1 (es) 2005-01-31
CA2529544A1 (en) 2004-12-29

Similar Documents

Publication Publication Date Title
IS8224A (is) Amínsölt (-)-2-{[2-(4-hýdroxýfenýl)etýl]-þíó}-3-[4-(2-{4-[(metýlsúlfónýl)oxý]fenoxý}etýl)fenýl]própansýru og notkun þeirra í læknisfræði
DK1658056T3 (da) Tabletter indeholdende 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionsyreethylester eller salte deraf
CY1109299T1 (el) Μεθανοσουλφονικο αλας 3-[(2-{[4-εξυλοξυκαρβονυλαμινο-ιμινο-μεθυλο)-φαινυλαμινο]-μεθυλο}-1-μεθυλο-1η-βενζιμιδαζολο-5-καρβονυλο)-πυριδιν-2-υλο-αμινο]-προπιονικου αιθυλεστερα και η χρηση αυτου ως φαρμακευτικο μεσο
CY2012031I2 (el) Χορηγουμενη απο του στοματος φαρμακοτεχνικη μορφη για τον 3-[(2-{[4-(εξυλοξυκαρβονυλαμινο-ιμινο-μεθυλο)-φαινυλαμινο]-μεθυλ}-1-μεθυλ-1η-βενζιμιδαζολο-5-καρβονυλο)-πυριδιν-2-υλ-αμινο]-προπιονικο αιθυλεστερα ή τα αλατα αυτου
DK1466912T3 (da) 2-acylaminothiazolderivat eller salt deraf
IL186435A (en) Pharmaceutical formulation for oral administration of choline salt of acid 2 - [4 - (4 - chlorobenzoyl) phenoxy] - 2 - methyl propanoic
LU92555I2 (fr) Empagliflozine et ses sels, en particulier Empagliflozine (*) (*) l'ingrédient actif approuvé est l'Empagliflozine de formule (1S)-1,5anhydro-1-C-{4-chloro-3-¬(4-{¬(3S)-oxolan-3-yloxyl}phényl)méthylphényl}-D-glucitol
EE200200284A (et) (S)-2-etoksü-3-[4-(2-{4-metaansulfonüüloksüfenüül}etoksü)fenüül]propaanhappe peenestatud vorm
DE60336251D1 (de) Identifikation von aufzeichnungsmedien
DE602004022179D1 (de) 4-((phenoxyalkyl)thio)-phenoxyessigsäuren und analoga
IS8234A (is) Kalíum- eða natríumsalt (-)-2-{[2-(4-hýdroxýfenýl)etýl]þíó}-3-[4-(2-{4-[(metýlsúlfónýl)oxý]fenoxý}fenýl]própansýru og notkun þeirra í læknisfræði
IL172376A0 (en) Process for the preparation of racemic 2{[2-(4- hydroxyphenyl)ethyl]thio}-3-[4-(2-{4- [(methylsulphonyl)oxy]phenoxy}ethyl)phenyl]-propanoic acid
DE602004018622D1 (de) Pharmazeutische zusammensetzung enthaltend 5-methyl-2-2'-(chloro-6'-fluoroanilino)phenylessigsäure
ATE425963T1 (de) Sulfonsauresalze von mandelsaurederivaten
IS7056A (is) Lyfjablanda sem annaðhvort felur í sér (S)-2-etoxý-3 [4-(2-{4-metansúlfónýloxýfenýl} etoxý)fenýl] própansýru eða 3-{4-[2-(4-tert-bútoxýkarbónýlamínófenýl)etoxý]fenýl}-(S)-2-etoxý própansýru og insúlín
IS7057A (is) Lyfjablanda sem annaðhvort felur í sér (S)-2-etoxý-3-[4-(2-{4-metansúlfónýloxýfenýl} etoxý)fenýl] própansýru eða 3-{4-[2-(4-tert-bútoxýkarbónýlamínófenýl)etoxý]fenýl}-(S)-2-etoxýprópansýru og súlónýlþvagefni
DE60316792D1 (de) Pharmazeutische verwendung von cox-2-hemmern in angiogenese-vermittelten augenerkrankungen
FR2879312B1 (fr) Procede d'ecriture et de restauration de donnees de conservation
ATE423569T1 (de) Verwendung von hitzelabilem escherichia-coli- toxin als adjuvans bei geflügel
FR2887148B1 (fr) Procede d'obtention d'un principe actif anti-age et principe actif obtenu
AR051998A1 (es) Agentes terapeuticos
DE60328787D1 (de) Pharmazeutische salze von reboxetin
NO20035237D0 (no) Farmasöytisk kombinasjon omfattende enten (S) -2-etoksy-3-(4- (2- (4-metansulfonyloksyfenyl) etoksy) fenyl) propansyre eller 3- (4- (2- (4-tert-butoksykarbonylaminofenyl) etoksy) fenyl)
TH95774A (th) สูตรผสมทางเภสัชกรรมชนิดน้ำของ 4-[((4-คาร์บอกซีบิวทิล)-{2-[(4-เฟนเนทธิลเบนซิล)ออกซี]เฟนเนทธิล}อะมิโน)เมทธิล]เบนโซอิคแอซิด
DK2189446T3 (da) Nye 4-{3-[4-(3-{4-[amino(butoxycarbonylimino)methyl]phenoxy}propyl)-1-piperidinyl]propoxy]-N´-(butoxycarbonyl)benzadimin-krystaller